STAG Industrial

EastGroup Properties

Equinix

One Liberty Properties

EPR Properties

American Tower

Healthcare Realty Trust Inc

Gaming and Leisure Properties

Apartment Income REIT Corp

CTO Realty Growth

GRI Bio Inc

RDOG tracks an equal-weighted index that selects the five highest yielding US REITs within nine REIT segments.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

LA JOLLA, CA, April 29, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstracts have been accepted for presentation at the 14 th International Congress on Autoimmunity being held May 17-20, 2024 in Ljubljana, Slovenia.

GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity

Live webcast on Wednesday, May 1 st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:00 PM ET.

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA.

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024

GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update

Live webcast on Wednesday, April 3 rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference

Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases

GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators

MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) with interim data expected H1 2024 and topline data H2 2024

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

ProSomnus Inc

Panbela Therapeutics Inc

SINTX Technologies Inc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)

GRI Bio (NASDAQ: GRI ) stock is taking a beating on Friday as investors in GRI react to the pricing of a public offering for the biotechnology company's shares. According to a press release from GRI Bio, this public offering includes 5 million shares of GRI stock priced at $1.10 each.

Why Is GRI Bio (GRI) Stock Down 21% Today?

LA JOLLA, CA, Feb. 02, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pricing of its “reasonable best efforts” public offering (the “Offering”) with participation from healthcare focused institutional investors for the purchase and sale of 5,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.10 per share. The Company further agreed to issue to the investors Series B-1 Warrants to purchase up to 5,000,000 shares of common stock and Series B-2 Warrants to purchase up to 5,000,000 shares of common stock. The Series B-1 and Series B-2 Warrants will have an exercise price of $1.10 per share, will be exercisable immediately following the date of issuance and will expire in five years and eighteen months, respectively.

GRI Bio Announces Pricing of $5.5 Million Public Offering

Allovir, Inc.

iBio

Vyne Therapeutics

The most oversold stocks in the health care presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)

Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 1 LA JOLLA, CA, Dec. 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the initiation of patient enrollment in the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF. Patient dosing is expected imminently.

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Clinical development plan leveraging 505(b)(2) regulatory pathway Initiation of Phase 2a biomarker study on track to start before year end Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited compliance and no impact on survival 1 Management discusses IND clearance and what this milestone means in a brief video: here LA JOLLA, CA, Nov. 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (“IND”) application for GRI-0621 for the treatment of IPF. The Company plans to evaluate GRI-0621 in a randomized, double-blind, multi-center Phase 2a biomarker study, on track to commence before year end.

GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024

GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Data presented at the 7 th Annual Antifibrotic Drug Development (AFDD) Summit Company's lead program, GRI-0621, has demonstrated ability to inhibit the activity of type I invariant NKT (iNKT) cells early in the inflammatory cascade to prevent cytokine release, cellular infiltration, and interrupts disease progression at the source Daily oral administration of GRI-0621 (a human equivalent dose) leads to reduced lung damage and a significant reduction in Bleomycin-induced lung fibrosis LA JOLLA, CA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the presentation of data supporting its novel approach to inflammatory diseases at the 7th Annual Antifibrotic Drug Development (AFDD) Summit held October 24-26, 2023 in Boston, MA. As part of the AFDD Summit, Vipin Kumar, PhD, Chief Scientific Officer of GRI Bio gave an oral presentation titled, “Exploration of NKT Cell Activation as an Immune Biomarker for Progression of Fibrosis,” and participated in a panel discussion titled, Reviewing Biomarkers Discussed in the Context of Fibrosis & Oncology, which discussed the promising new avenues for evaluating fibrosis staging in vivo, in vitro and in patient; review the advantages and pitfalls of fluid markers vs imaging for fibrosis diagnostics; and illuminate similarities and differences in biomarkers across fibrotic disease and tumor fibrosis.

GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases

Findings demonstrate that the number of NKT cells positively correlates with the number of airway macrophages in IPF patients

GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference

UK consortia brings together internationally recognized investigators in the UK's leading centers of excellence to carry out experimental and early phase research

GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression

- Live moderated webcast with Marc Hertz, Chief Executive Officer of GRI Bio on Tuesday, October 24 th at 11:00 AM ET

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference

In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting

GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions

LA JOLLA, CA / ACCESSWIRE / September 29, 2023 / September is Pulmonary Fibrosis Awareness Month - a time dedicated to raising public consciousness and understanding about this devastating lung disease. Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and ultimately fatal condition that causes scarring and thickening of the lungs, making it more and more difficult for patients to breathe.

September Is Pulmonary Fibrosis Awareness Month: Here's What One Company Is Doing To Develop A Treatment For This Deadly Disease

LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.

GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference

LA JOLLA, CA / ACCESSWIRE / September 1, 2023 / Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is unknown, but it is believed to involve a combination of genetic and environmental factors.

IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution?

La Jolla, California--(Newsfile Corp. - August 29, 2023) - GRI Bio, Inc. (NASDAQ: GRI), a clinical-stage biotechnology company developing novel immunotherapies that modulate natural killer T (NKT) cells, today announced it has engaged B2i Digital, Inc. ("B2i") to execute an innovative digital engagement and awareness program. B2i brings together decades of experience from public relations, investment banking, and digital marketing to advise on and develop marketing campaigns to target appropriate stakeholders.

GRI Bio Engages B2i Digital to Deploy Cutting-Edge Engagement Campaign

LA JOLLA, CA / ACCESSWIRE / August 25, 2023 / Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that are more widely known are Idiopathic Pulmonary Fibrosis (IPF) and Lupus.

News for GRI Bio Inc Stock (GRI)